U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. Clinical Trial Endpoint Development for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) - 11/03/2021
  1. FDA Meetings, Conferences and Workshops

Workshop | Virtual

Event Title
Clinical Trial Endpoint Development for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
November 3, 2021

Date:
November 3, 2021
Organized By:
Organizer

Twitter: #OCE2021HNSCC

Sponsored by the U.S. Food & Drug Administration (FDA)

Background:

The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) welcomes you to the Clinical Trial Endpoint Development for Locally Advanced Head and Neck Cancer public virtual workshop. Throughout the day you will hear interactive discussions on early endpoints in locally advanced head and neck squamous cell carcinoma, event-free survival (EFS) and locoregional control (LRC), issues regarding management and defining early endpoints, and patient’s perspective on clinical trial endpoints.

Meeting goals:

  • Provide a forum for open discussion between academia, regulatory, and patient advocacy groups on clinical trial endpoint development for locally advanced head and neck cancer.
  • Identify the current status of early endpoints for locally advanced head and neck cancer and how it differs from other cancers.
  • Engage stakeholders to identify concerns regarding standardization of endpoint definitions and clinical trial design.

Workshop Materials

  • Agenda (PDF 168KB)
  • Biographies  (PDF- 1.62 MB)
  • Session I: Clinical Trials in Non-Metastatic HNSCC
  • Session II: Defining Early Endpoints and Issues Regarding Management After Definitive Therapy
  • Session III: Patient Perspective on Clinical Trials for Locally Advanced HNSCC
  • Session IV: Early Endpoints in Locally Advanced HNSCC
  • Session V: EFS as an Endpoint in Locally Advanced HNSCC Clinical Trials
  • Session VI: LRC as an Endpoint in Locally Advanced HNSCC Clinical Trials
  • Session VII: Patient Reported Outcomes

Webcast

Event Point of Contacts

Angela James, RN, MSN
Senior Regulatory Health Project Manager
Oncology Center of Excellence
Office of the Commissioner
U.S. Food and Drug Administration
10903 New Hampshire Avenue, Silver Spring, MD 20993
Tel: 301-796-6122
Angela.James@fda.hhs.gov

Christine Lincoln, RN, MS, MBA
Senior Regulatory Health Project Manager
Oncology Center of Excellence
Office of the Commission
U.S. Food and Drug Administration
10903 New Hampshire Avenue, Silver Spring, MD 20993
Tel: 301-796-4117
Christine.Lincoln@fda.hhs.gov

 

Event Materials

Title File Type/Size
November 3, 2021: FDA Public Workshop Speaker Biographies pdf (1.62 MB)
Back to Top